News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
POLICY
Zhou Siyuan Nominated as China Center for Drug Evaluation's New Director
China’s Center for Drug Evaluation (CDE) recently revealed a change in its leadership—Zhou Siyuan replaces Kong Fanpu as the new director. As an office under the National Medical Products Administration (NMPA), CDE is mostly known for its function of conducting technical review/evaluation of drug registration applications.
Aug 30, 2023
POLICY
China Encourages Pediatric Drugs' Development and Marketing Authorization
On Aug. 23, 2023, China released the 4th List of Pediatric Drugs Encouraged for Development and Marketing Authorization. The list contains 24 drugs, involving 30 strengths, 9 dosage forms, and multiple therapeutic areas such as nervous system diseases, gastrointestinal system, metabolic disorders, tumors, and immune disease.
Aug 24, 2023
POLICY
Law & Regulation
Marketing Approval
Volume-based Procurement
Health Insurance
Innovative Drug
Cancer
Cardiovascular Disease
Rare Disease
Drug Registration
New Drug
China's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry
China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022
Most Popular
- Monthly Report: New Drug Approvals in China | February 2024
- Monthly Recap: China Pharmaceutical Regulatory Updates | February 2024
- 2023 China CDE Drug Evaluation Report
- [Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China
- Monthly Report: New Drug Approvals in China | March 2024